AI Article Synopsis
Article Abstract
Objective: Diagnostic ureterorenoscopy is used to identify upper tract urothelial cancer before radical nephro ureterectomy, especially for uncertain lesions in imaging modalities or urine cytology. However, diagnostic ureterorenoscopy can potentially cause intravesical tumor spillage and can increase intravesical recurrence rates. We aimed to investigate the impact of diagnostic ureterorenoscopy before radical nephroureterectomy, with and without biopsy, on intravesical recurrence rates of patients with upper tract urothelial cancer.
Material And Methods: Patients with localized upper tract urothelial cancer from 8 different tertiary referral centers, who underwent radical nephroureterectomy between 2001 and 2020, were included. Three groups were made: no URS (group 1); diagnostic ureterorenoscopy without biopsy (group 2); and diagnostic ure terorenoscopy with biopsy (group 3). Intravesical recurrence rates and survival outcomes were compared. Univariate and multivariate Cox regression analyses were performed to determine the factors that were asso ciated with intravesical recurrence-free survival.
Results: Twenty-two (20.8%), 10 (24.4%), and 23 (39%) patients experienced intravesical recurrence in groups 1, 2, and 3, respectively (P=.037) among 206 patients. The 2-year intravesical recurrence-free sur vival rate was 83.1%, 82.4%, and 69.2%, for groups 1, 2, and 3, respectively (P=.004). Cancer-specific survival and overall survival were comparable (P=.560 and P=.803, respectively). Diagnostic ureterore noscopy+biopsy (hazard ratio: 6.88, 95% CI: 2.41-19.65, P < .001) was the only independent predictor of intravesical recurrence in patients with upper tract urothelial cancer located in the kidney, according to tumor location.
Conclusion: Diagnostic ureterorenoscopy+biopsy before radical nephroureterectomy significantly increased the rates of intravesical recurrence in tumors located in kidney. This result suggests tumor spillage with this type of biopsy, so further studies with different biopsy options or without biopsy can be designed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797743 | PMC |
| http://dx.doi.org/10.5152/tud.2022.22143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER.
Cancer Res
December 2024
Genesis Biotechnology Group, Hamilton, NJ, United States.
Bacillus Calmette-Guerin (BCG) is the current standard of care for non-muscle invasive bladder cancer (NMIBC), but recurrence is common. Additional therapeutic options are a major unmet medical need for treating unresponsive patients. Stimulator of Interferon Genes (STING) plays a central role in mounting innate and adaptive immune responses to tumor cells, and activation of STING is a promising immunotherapeutic approach.
View Article and Find Full Text PDFPredicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.
Transl Cancer Res
November 2024
Department of Urology, Ohio State University Wexner Medical Centre/The James Cancer Hospital, Columbus, OH, USA.
Bladder cancer is a commonly diagnosed cancer, especially in men, and 70% of new diagnoses are considered non-muscle invasive bladder cancer (NMIBC). Bladder cancer is prone to high rates of recurrence, and this risk is greatest in high risk NMIBC. Intravesical bacillus Calmette-Guerin (BCG) is standard of care for reducing rates of recurrence for high risk NMIBC.
View Article and Find Full Text PDFBackground And Objective: Non-muscle-invasive bladder cancer (NMIBC) patients treated with additional bacillus Calmette-Guérin (BCG) may become unresponsive to BCG. Recently, sequential intravesical gemcitabine and docetaxel (gem/doce) are being used for NMIBC. This study aims to compare oncologic outcomes between sequential intravesical gem/doce versus additional BCG in patients with BCG-unresponsive NMIBC.
View Article and Find Full Text PDFAssociation Between Hypoglycemia Agents and Long-term Survival Outcomes for Patients with Non-muscle-invasive Bladder Cancer Treated with Intravesical Bacillus Calmette-Guérin Immunotherapy.
Eur Urol Oncol
December 2024
S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China; Department of Urology, Medical University of Vienna, Austria, Vienna. Electronic address:
Background And Objective: There is a lack of data on the impact of hypoglycemia agents, especially metformin, on prognosis for non-muscle-invasive bladder cancer (NMIBC). Our aim was to investigate the association between hypoglycemia agents, especially metformin, and long-term survival outcomes for patients with NMIBC treated with bacillus Calmette-Guérin.
Methods: All patients with NMIBC treated with intravesical BCG therapy from 2001 to 2020 were identified in a territory-wide database in Hong Kong.
Magnetic-Powered Spora Lygodii Microrobots Loaded with Doxorubicin for Active and Targeted Therapy of Bladder Cancer.
Drug Des Devel Ther
December 2024
South China Hospital, Medical School, Shenzhen University, Shenzhen, 518116, People's Republic of China.
Background And Purpose: Bladder cancer has high recurrence rates despite standard treatments, necessitating innovative therapeutic approaches. This study introduces magnetically powered microrobots utilizing Traditional Chinese Medicine (TCM) Spora Lygodii (SL) encapsulated with Doxorubicin (DOX) and FeO nanoparticles (Fe/DOX@SL) for targeted therapy.
Methods: FeO nanoparticles were synthesized via co-precipitation and combined with SL spores and DOX through dip-coating to form Fe/DOX@SL microrobots.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!